NZ596244A - Treatment of neurodegenerative diseases - Google Patents

Treatment of neurodegenerative diseases

Info

Publication number
NZ596244A
NZ596244A NZ596244A NZ59624407A NZ596244A NZ 596244 A NZ596244 A NZ 596244A NZ 596244 A NZ596244 A NZ 596244A NZ 59624407 A NZ59624407 A NZ 59624407A NZ 596244 A NZ596244 A NZ 596244A
Authority
NZ
New Zealand
Prior art keywords
cell
treatment
neurodegenerative diseases
selenate
vitro
Prior art date
Application number
NZ596244A
Other languages
English (en)
Inventor
Christopher Hovens
Niall Corcoran
Original Assignee
Velacor Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velacor Therapeutics Pty Ltd filed Critical Velacor Therapeutics Pty Ltd
Publication of NZ596244A publication Critical patent/NZ596244A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NZ596244A 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases NZ596244A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78724006P 2006-03-29 2006-03-29
PCT/AU2007/000391 WO2007109851A1 (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
NZ596244A true NZ596244A (en) 2013-05-31

Family

ID=38540722

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ596244A NZ596244A (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases
NZ571835A NZ571835A (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ571835A NZ571835A (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Country Status (14)

Country Link
US (2) US8920851B2 (enExample)
EP (1) EP2004204B1 (enExample)
JP (1) JP5542430B2 (enExample)
KR (1) KR101451439B1 (enExample)
CN (1) CN101478977B (enExample)
AU (1) AU2007231547B2 (enExample)
BR (1) BRPI0709033A2 (enExample)
CA (1) CA2644441C (enExample)
DK (1) DK2004204T3 (enExample)
ES (1) ES2394348T3 (enExample)
MX (1) MX2008012479A (enExample)
NZ (2) NZ596244A (enExample)
RU (1) RU2489155C2 (enExample)
WO (1) WO2007109851A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005276117C1 (en) 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
AU2007231547B2 (en) 2006-03-29 2012-07-12 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
WO2007127273A2 (en) * 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
WO2009043116A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Methods and compositions for the treatment of phosphatase- related disorders
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis
CA2706203A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
JP5328244B2 (ja) * 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
EP3263127B1 (en) 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2016150403A1 (en) 2015-03-26 2016-09-29 Fujian Tiantai Medical Technology Co. Ltd Method of diagnosis or treatment of neurological disorders with p75ecd and/or p75
WO2019216589A1 (ko) * 2018-05-09 2019-11-14 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
CA3104397C (en) * 2018-06-29 2023-08-01 Rejuvenate Biomed Pharmaceutical combination for use in age-related and/or degenerative diseases
JP7518852B2 (ja) 2019-03-26 2024-07-18 シアー， インコーポレイテッド 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用
WO2023029210A1 (zh) * 2021-08-31 2023-03-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
WO2023057422A1 (en) * 2021-10-06 2023-04-13 Bayer Aktiengesellschaft Universal buffer in methods for safe and rapid detection of pathogen infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPH04247033A (ja) * 1991-02-04 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 神経細胞壊死抑制剤
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US6524619B2 (en) 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
DE10059886A1 (de) 2000-12-01 2002-06-20 Basf Coatings Ag Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EA200501710A1 (ru) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые карбоновые кислоты
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20050142216A1 (en) 2003-12-31 2005-06-30 Rindlesbach Keith A. Method for reversing Alzheimer dementia
AU2005227420B2 (en) * 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
AU2007231547B2 (en) 2006-03-29 2012-07-12 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
CA2644445A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of benign tumors

Also Published As

Publication number Publication date
US20140141104A1 (en) 2014-05-22
BRPI0709033A2 (pt) 2011-06-21
KR101451439B1 (ko) 2014-10-16
NZ571835A (en) 2011-11-25
CA2644441A1 (en) 2007-10-04
RU2008142514A (ru) 2010-05-10
US8920851B2 (en) 2014-12-30
CN101478977B (zh) 2013-03-27
EP2004204A1 (en) 2008-12-24
RU2489155C2 (ru) 2013-08-10
US20090169649A1 (en) 2009-07-02
WO2007109851A1 (en) 2007-10-04
AU2007231547B2 (en) 2012-07-12
CA2644441C (en) 2014-09-09
ES2394348T3 (es) 2013-01-30
CN101478977A (zh) 2009-07-08
JP2009532340A (ja) 2009-09-10
JP5542430B2 (ja) 2014-07-09
EP2004204A4 (en) 2010-06-02
DK2004204T3 (da) 2013-01-07
KR20090015038A (ko) 2009-02-11
MX2008012479A (es) 2009-08-13
AU2007231547A1 (en) 2007-10-04
EP2004204B1 (en) 2012-09-12

Similar Documents

Publication Publication Date Title
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
AU2007257423A8 (en) Purine analogs
MX374396B (es) Rocio de fentanilo sublingual.
MX2010004074A (es) Combinacion 059.
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
MX2008012479A (es) Tratamiento de enfermedades neurodegenerativas.
MX2007005649A (es) Carboxiamidas de azaindol.
CA2837895C (en) Methods of treating or preventing neurological diseases
WO2007131232A3 (en) Compositions and their uses directed to ptpr alpha
IL189927A0 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
NZ597030A (en) Method for treatment of diseases
PT1778680E (pt) Derivados espirocíclicos de ciclo-hexano
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
WO2007147868A3 (en) Prevention of muscle atrophy
WO2006091841A3 (en) Compositions and their uses directed to il-4r alpha
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
SG195170A1 (en) Methods of treating or preventing rheumatic disease
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2007025229A3 (en) Compositions and their uses directed to hsp27
ATE462430T1 (de) Pharmazeutische zusammensetzung zur behandlung von inkontinenz
DE602005001918D1 (de) S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers
NO20092654L (no) Anvendelse av forbindelse

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 29/03/2007; THE PATENT COMPLETE SPECIFICATION DATE HAS BEEN CORRECTED TO 29/03/2007

Effective date: 20130506

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 MAR 2014 BY DAVIES COLLISON CAVE

Effective date: 20130904

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 MAR 2017 BY CPA GLOBAL

Effective date: 20140403

LAPS Patent lapsed